#1 Clinical Trials Search in Europe

Arginase deficiency – Diagnostics

Go back

Diagnosing arginase deficiency involves careful evaluation of symptoms, specialized blood tests, and genetic analysis to confirm the condition and guide treatment decisions. Early detection through newborn screening or prompt testing when symptoms appear can help prevent serious neurological problems and support better outcomes for affected individuals.

Introduction: Who Should Undergo Diagnostics

Arginase deficiency is a rare inherited disorder that affects how the body processes nitrogen from protein. Because this condition can cause serious health problems if left untreated, knowing when to seek diagnostic testing is important for families and healthcare providers. Diagnostics should be considered in several situations, each pointing toward the possibility that something may not be working correctly in the body’s waste disposal system.[1]

Newborns in some regions of the United States are now routinely screened for arginase deficiency as part of expanded newborn screening programs. This testing happens in the first few days of life, before any symptoms appear. When a screening test comes back with elevated levels of arginine (an amino acid that builds proteins), further testing is needed to confirm whether the baby truly has the condition. Early identification through newborn screening allows treatment to begin before any damage occurs to the nervous system.[2]

Children who were not screened at birth, or who live in areas where screening is not available, should undergo testing if they show certain warning signs. Parents and doctors should be alert to symptoms that typically appear between one and three years of age. These include unusual muscle stiffness, especially in the legs, slower growth than expected for the child’s age, and delays in reaching developmental milestones like walking or talking. If a child walks on their toes persistently, has difficulty moving their legs, or seems to be losing skills they once had, these are reasons to pursue diagnostic testing.[4]

Occasionally, children or even adults may experience episodes that suggest a buildup of ammonia in the blood. These episodes might happen after eating a high-protein meal, during an illness with fever, after surgery, or during periods without food. Symptoms of such episodes include vomiting, refusal to eat, extreme tiredness, irritability, or changes in mood or thinking. Anyone experiencing these symptoms, especially if they have a family history of metabolic disorders or unexplained neurological problems, should be evaluated for arginase deficiency.[3]

Some individuals have milder forms of arginase deficiency that do not appear until later in childhood, adolescence, or even adulthood. In these cases, the main symptom may be progressive stiffness in the legs, known as spastic paraparesis, which gradually worsens over time. People with unexplained spasticity, difficulty walking, or problems with bowel or bladder control should be tested, particularly if no other cause can be identified. This is important because arginase deficiency can sometimes be confused with other conditions like cerebral palsy.[5]

Family members of someone diagnosed with arginase deficiency may also benefit from testing, particularly if they are planning to have children. Because this condition is inherited in an autosomal recessive pattern, parents of an affected child each carry one changed copy of the gene. Genetic counseling and testing can help families understand their risks and make informed decisions about pregnancy and prenatal testing.[8]

⚠️ Important
If you or your child experiences sudden confusion, extreme sleepiness, repeated vomiting, or seizures, seek emergency medical care immediately. These could be signs of dangerously high ammonia levels in the blood, which require urgent treatment even though severe episodes are less common in arginase deficiency than in other similar disorders.

Diagnostic Methods for Identifying Arginase Deficiency

Once a doctor suspects arginase deficiency based on symptoms or a positive newborn screening result, several tests can be used to confirm the diagnosis and distinguish it from other conditions. The diagnostic process typically involves blood tests, genetic testing, and sometimes additional specialized studies. Each test provides different pieces of information that help doctors understand what is happening in the patient’s body.[4]

Blood Tests for Amino Acids and Ammonia

The most important initial test is a blood amino acid analysis, which measures the levels of different amino acids circulating in the bloodstream. In people with arginase deficiency, the amino acid arginine is found at very high levels—often up to four times higher than normal. This finding is considered pathognomonic for arginase deficiency, meaning it is so characteristic of the condition that it strongly points to this specific diagnosis when other symptoms are also present.[5]

The blood test is usually performed after a period of fasting or at a standard time of day to ensure accurate results. A healthcare provider will draw blood from a vein, typically in the arm, and send the sample to a specialized laboratory that can measure amino acid levels precisely. Results are usually available within a few days to a week. When arginine levels are highly elevated, further testing is needed to confirm the diagnosis and rule out other causes.[14]

Doctors may also check the level of ammonia in the blood. Unlike other urea cycle disorders (the group of conditions to which arginase deficiency belongs), people with arginase deficiency do not always have severely elevated ammonia. Many affected individuals have normal or only slightly increased ammonia levels most of the time. However, during episodes of illness, stress, or high protein intake, ammonia can rise more quickly. For this reason, a single normal ammonia test does not rule out arginase deficiency.[2]

Genetic Testing

After blood tests suggest arginase deficiency, genetic testing is performed to confirm the diagnosis. This involves analyzing the ARG1 gene, which provides instructions for making the arginase enzyme. In people with arginase deficiency, both copies of this gene contain harmful changes called pathogenic variants or mutations. Genetic testing looks for these changes to provide definitive proof of the diagnosis.[8]

Genetic testing typically requires a blood sample, though sometimes a saliva sample or cheek swab can be used. The sample is sent to a molecular genetics laboratory where technicians examine the DNA sequence of the ARG1 gene. The laboratory will identify any variants and classify them as pathogenic (disease-causing), likely pathogenic, benign (harmless), or of uncertain significance. When two pathogenic or likely pathogenic variants are found, the diagnosis is confirmed.[5]

In rare cases, genetic testing may find variants of uncertain significance (VUS), meaning the laboratory cannot be sure whether the changes are harmful or harmless. When this happens, additional testing may be needed to clarify the diagnosis. Results from genetic testing usually take several weeks to several months, depending on the laboratory and the complexity of the analysis.[14]

Enzyme Activity Testing

Although less commonly performed today, enzyme activity testing can be helpful when genetic test results are unclear or when a diagnosis needs to be confirmed quickly. This test measures how well the arginase enzyme is working in red blood cells. In people with arginase deficiency, the enzyme activity is usually less than one percent of normal levels.[4]

The test requires a blood sample that is processed in a specialized laboratory. Technicians extract the red blood cells and measure how much arginine the cells can break down over a specific time period. Very low or absent enzyme activity supports the diagnosis of arginase deficiency. However, because genetic testing has become more widely available and provides more specific information, enzyme testing is now used primarily when genetic results are inconclusive.[5]

Additional Laboratory Studies

Doctors may order other laboratory tests to assess the effects of arginase deficiency on the body and to monitor for complications. These tests do not diagnose the condition itself but provide important information about a patient’s overall health. One such test measures orotic acid in the urine, which can be elevated in some urea cycle disorders. Results may help distinguish arginase deficiency from other similar conditions.[12]

Liver function tests are often performed because arginase is primarily found in the liver. Some people with arginase deficiency develop mild liver problems over time. Blood tests that measure liver enzymes, proteins made by the liver, and other markers of liver health can help doctors detect any liver dysfunction early so it can be monitored or treated if necessary.[5]

Imaging and Other Studies

While blood and genetic tests provide the main evidence for diagnosis, doctors sometimes use imaging studies or other evaluations to understand how the condition is affecting the body, particularly the brain and nervous system. These tests are not used to make the initial diagnosis but can help assess the severity of the condition and guide treatment decisions.[4]

Brain imaging with magnetic resonance imaging (MRI) may be performed in some patients, especially those with significant neurological symptoms like developmental delays, seizures, or severe spasticity. The MRI can show whether there are any changes in the structure or appearance of the brain tissue. However, brain MRI findings in arginase deficiency are often nonspecific, meaning they do not point to this particular diagnosis but may show general signs of neurological involvement.[7]

Newborn Screening

In regions where expanded newborn screening is available, arginase deficiency can be detected before any symptoms appear. The screening test uses a few drops of blood collected from the baby’s heel onto a special paper card, usually when the baby is one to two days old. The blood spot is sent to a state laboratory where it is analyzed using tandem mass spectrometry, a technology that can measure many different substances at once, including amino acids like arginine.[21]

If the screening test shows elevated arginine levels, the baby is recalled for additional testing. It is important to understand that a positive screening test does not mean the baby definitely has arginase deficiency—it means further evaluation is needed. Follow-up testing with a complete blood amino acid analysis and genetic testing will either confirm or rule out the diagnosis. Babies identified through newborn screening who are diagnosed early and treated promptly appear to have better outcomes than those diagnosed later after symptoms develop.[2]

Distinguishing Arginase Deficiency from Other Conditions

Because symptoms of arginase deficiency can overlap with other medical conditions, part of the diagnostic process involves ruling out alternative explanations. The progressive leg stiffness seen in arginase deficiency can be mistaken for cerebral palsy, a group of movement disorders caused by brain damage before or during birth. However, cerebral palsy does not cause worsening symptoms over time or elevated arginine levels in the blood.[4]

If high ammonia levels are the main finding, doctors must consider other urea cycle disorders as well as secondary causes of hyperammonemia (excess ammonia in the blood). These include other enzyme deficiencies in the urea cycle, certain organic acidurias (conditions affecting the breakdown of amino acids and fats), mitochondrial diseases, and liver failure. Blood amino acid patterns, urine organic acid analysis, and genetic testing help distinguish these conditions from one another.[14]

When spasticity without hyperammonemia is the primary concern, doctors may consider hereditary spastic paraplegias, other genetic conditions affecting movement, or structural problems with the spinal cord. The combination of progressive spasticity, developmental regression, and elevated blood arginine is distinctive for arginase deficiency and helps separate it from these other possibilities.[5]

⚠️ Important
A diagnosis of arginase deficiency should always be made by a healthcare provider experienced in metabolic disorders, such as a metabolic specialist or medical geneticist. These specialists understand how to interpret complex test results and can coordinate the care team needed to manage this rare condition effectively.

Diagnostics for Clinical Trial Qualification

As researchers work to develop new treatments for arginase deficiency, clinical trials are testing experimental therapies that may help people with this condition. To participate in a clinical trial, potential participants must meet specific criteria established by the researchers. These criteria ensure that the trial enrolls people who are most likely to benefit from the experimental treatment and who can be safely monitored throughout the study.[21]

The first and most fundamental requirement for any arginase deficiency clinical trial is confirmation of the diagnosis. This typically requires documented genetic testing showing two pathogenic variants in the ARG1 gene. Some trials may also accept participants with documented arginase enzyme deficiency in red blood cells if genetic testing is incomplete or inconclusive. The trial team will review all diagnostic records to verify that the participant truly has arginase deficiency and not another condition.[8]

Clinical trials often have age requirements. Some trials focus on children, while others may include adults. Participants must fall within the specified age range at the time of enrollment. The trial may also have requirements about disease severity or the presence of specific symptoms. For example, a trial testing a treatment for spasticity might require participants to have measurable muscle stiffness, while a trial aimed at preventing symptoms might focus on newly diagnosed infants who have not yet developed problems.[10]

Before enrolling in a clinical trial, participants undergo baseline testing to establish their current health status. This testing serves several purposes: it helps researchers understand the starting point before treatment begins, it ensures the person is healthy enough to participate safely, and it provides data that will be compared to later measurements to see if the treatment is working. Baseline tests for arginase deficiency trials typically include blood tests to measure arginine and ammonia levels, comprehensive metabolic panels to assess liver and kidney function, and complete blood counts.[8]

Neurological assessments are often part of the qualification process for clinical trials in arginase deficiency. These may include standardized tests of motor function to measure spasticity and walking ability, cognitive testing to evaluate thinking and learning skills, and assessments of developmental milestones in children. Some trials use specialized scales or questionnaires to measure quality of life, daily functioning, or symptom severity. These assessments provide objective measurements that can be repeated during the trial to see if the experimental treatment is making a difference.[4]

Participants may need to undergo imaging studies as part of trial qualification. Brain MRI scans can show the extent of any neurological changes and provide a baseline for comparison if repeat scans are performed during the trial. Some trials may also include other specialized studies, such as tests of nerve conduction or muscle activity, to better understand how the disease is affecting the nervous system.[7]

Clinical trials have exclusion criteria—conditions or circumstances that prevent someone from participating. Common exclusions include having other serious medical conditions that could interfere with the trial, taking certain medications that might interact with the experimental treatment, being pregnant or breastfeeding, or having had a liver transplant. Some trials exclude people who have already tried other experimental treatments or who are currently enrolled in a different trial. The specific exclusion criteria vary depending on the trial design and the treatment being tested.[10]

Throughout the screening process for trial qualification, potential participants work closely with the trial coordinator and medical team. This team reviews all medical records, performs required testing, and ensures that every aspect of the inclusion and exclusion criteria is carefully evaluated. The goal is to determine whether the trial is appropriate for the individual and whether the individual meets all requirements for safe and meaningful participation.[8]

It is important to understand that meeting the diagnostic criteria for arginase deficiency does not automatically qualify someone for every clinical trial. Each trial has its own specific requirements based on the research questions being asked and the treatment being studied. Families interested in clinical trial participation should discuss options with their metabolic specialist, who can help identify relevant trials and determine whether the patient might be eligible.[21]

Prognosis and Survival Rate

Prognosis

The outlook for people with arginase deficiency varies significantly depending on when the condition is diagnosed and how well it is managed. Individuals who are identified early through newborn screening and receive prompt treatment appear to have minimal symptoms and much better outcomes than those diagnosed later after symptoms have developed. When treatment begins before any neurological damage occurs, many children can achieve normal or near-normal growth and development.[8]

For children diagnosed after symptoms appear, the prognosis depends on the severity of symptoms at diagnosis and how quickly treatment is started. Without treatment, arginase deficiency is a progressive disease, meaning it tends to worsen over time. Untreated individuals typically develop severe spasticity that makes walking difficult or impossible, lose bowel and bladder control, and experience severe intellectual disability. They may also lose developmental skills they once had, a process called developmental regression.[3]

With appropriate treatment including dietary protein restriction, medical formula, and nitrogen-scavenging medications, progression of symptoms can often be slowed or stopped. Some people experience improvement in certain symptoms, particularly if treatment is started relatively early. However, neurological damage that has already occurred before treatment began may not be reversible. This is why early diagnosis and prompt treatment are so important.[5]

The disease course is highly variable between individuals, even among those receiving treatment. Some people have milder forms of the condition that progress more slowly and cause less severe disability. Others have more aggressive disease despite good medical management. No specific genetic changes have been identified that reliably predict how severe an individual’s condition will be, making it difficult to forecast outcomes at the time of diagnosis.[2]

Unlike some other urea cycle disorders, life-threatening episodes of severe hyperammonemia leading to coma are uncommon in arginase deficiency. However, they can occur, particularly during times of illness, stress, or surgery. With prompt recognition and treatment of these episodes, most people recover without lasting effects. The main factors affecting long-term prognosis are the progressive neurological problems rather than acute metabolic crises.[5]

Survival Rate

Life expectancy is limited in most patients with arginase deficiency, though specific survival statistics are difficult to determine because the condition is so rare. In the past, when the condition often went undiagnosed or was diagnosed late, survival was significantly shortened. Many affected individuals did not survive into adulthood due to progressive neurological decline and complications.[5]

With modern management including early diagnosis through newborn screening, dietary treatment, and nitrogen-scavenging medications, survival appears to be improving. Some individuals diagnosed and treated from birth are now living into their teenage years and beyond with relatively good quality of life. However, long-term outcome data for these early-diagnosed patients is still being collected as the expanded newborn screening programs that detect arginase deficiency are relatively recent.[21]

For those diagnosed later after symptoms have developed, life expectancy varies based on disease severity and complications. Severe spasticity can lead to joint contractures and limited mobility, increasing the risk of complications like pneumonia and pressure sores. Seizures, when present, are usually well-controlled with medication. Liver dysfunction occurs in some patients but is typically mild. In rare cases, progression to liver fibrosis and cirrhosis may occur.[8]

Ongoing Clinical Trials on Arginase deficiency

  • Title: Safety and effectiveness study of pegzilarginase weekly injections in children under 2 years old with Arginase 1 Deficiency

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Portugal

References

https://medlineplus.gov/genetics/condition/arginase-deficiency/

https://www.ncbi.nlm.nih.gov/books/NBK482365/

https://www.newenglandconsortium.org/mcb-arginase

https://www.childneurologyfoundation.org/disorder/arginase-1-deficiency-arg1-d/

https://www.orpha.net/en/disease/detail/90

https://nucdf.org/about-ucd/what-is-a-ucd/types-of-ucds/arginase.html

https://emedicine.medscape.com/article/941838-overview

https://www.ncbi.nlm.nih.gov/books/NBK1159/

https://www.ncbi.nlm.nih.gov/books/NBK482365/

https://emedicine.medscape.com/article/941838-treatment

https://www.childneurologyfoundation.org/disorder/arginase-1-deficiency-arg1-d/

https://www.newenglandconsortium.org/arginase-deficiency

https://myriad.com/womens-health/diseases/argininemia/

https://www.orpha.net/en/disease/detail/90

https://www.newenglandconsortium.org/mcb-arginase

https://www.immedica.com/en/stories/brie-and-vanessa-sharing-life-arginase-1-deficiency

https://www.ncbi.nlm.nih.gov/books/NBK482365/

https://www.childneurologyfoundation.org/disorder/arginase-1-deficiency-arg1-d/

https://arg1d.org/

https://medlineplus.gov/genetics/condition/arginase-deficiency/

https://emedicine.medscape.com/article/941838-treatment

More information about
Arginase deficiency:

FAQ

How accurate is newborn screening for arginase deficiency?

Newborn screening for arginase deficiency using tandem mass spectrometry is quite sensitive and can detect elevated arginine levels in affected babies. However, screening tests are not perfect—they can have false positives (the test suggests disease when the baby is healthy) or rarely miss cases. Any positive screening result requires follow-up testing with a complete blood amino acid analysis and genetic testing to confirm or rule out the diagnosis.[2]

Can arginase deficiency be diagnosed during pregnancy?

Yes, prenatal diagnosis is possible if the condition is known to run in the family. Genetic testing can be performed on cells obtained through chorionic villus sampling (usually done at 10-13 weeks of pregnancy) or amniocentesis (usually done at 15-20 weeks). This testing looks for the same ARG1 gene changes found in an affected family member. Prenatal diagnosis requires that the specific mutations in the family are already known from testing a previously affected child.[21]

Why is arginine level so high in this condition when it’s low in other urea cycle disorders?

Arginase is the enzyme responsible for breaking down arginine in the final step of the urea cycle. When this enzyme doesn’t work properly, arginine accumulates because it cannot be converted to ornithine and urea. In contrast, other urea cycle disorders affect earlier steps in the cycle, preventing arginine from being formed in the first place. This makes elevated arginine highly specific for arginase deficiency among the urea cycle disorders.[14]

Do I need to fast before blood tests for arginase deficiency?

Fasting requirements vary by laboratory and the specific tests being ordered. For amino acid analysis, some laboratories prefer a fasting sample (typically 4-8 hours for infants and children) while others can work with non-fasting samples. Your doctor or the laboratory will provide specific instructions. For ammonia testing, fasting is usually preferred but must be balanced against the risk of triggering symptoms from prolonged fasting in someone with a metabolic disorder.[4]

How long does it take to get genetic test results for arginase deficiency?

Genetic testing typically takes several weeks to several months, depending on the laboratory and the type of testing ordered. Standard sequencing of the ARG1 gene usually takes 2-4 weeks for results. More comprehensive testing that looks for deletions, duplications, or other complex changes may take longer. If your doctor orders urgent testing or if you’re participating in a newborn screening follow-up, results may be expedited.[8]

🎯 Key Takeaways

  • • Early diagnosis through newborn screening offers the best chance for preventing severe neurological problems in arginase deficiency, even though most babies appear completely healthy at birth.
  • • Extremely high blood arginine levels are the hallmark of arginase deficiency and distinguish it from all other urea cycle disorders, making this blood test crucial for diagnosis.
  • • Children with progressive leg stiffness and developmental delays should be tested for arginase deficiency, as the condition can be mistaken for cerebral palsy or other movement disorders.
  • • Genetic testing confirming two disease-causing changes in the ARG1 gene provides definitive diagnosis and is required for participation in clinical trials testing new treatments.
  • • Unlike other urea cycle disorders, severe ammonia crises are uncommon in arginase deficiency, but can still occur during illness or stress, requiring vigilance even with normal baseline ammonia levels.
  • • Diagnosis should be made by specialists experienced in metabolic disorders who can coordinate the complex testing and interpret results in the context of the patient’s symptoms and family history.
  • • The rarity of arginase deficiency (occurring in only 1 in 300,000 to 1,000,000 births) means many healthcare providers have never encountered a case, underscoring the importance of specialist involvement.

Connected medications: